Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veru Inc VERU

Consumer Defensive Household & Personal Products
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed in two different programs... see more

Recent & Breaking News (NDAQ:VERU)

FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients

GlobeNewswire May 11, 2022

FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study

GlobeNewswire May 2, 2022

Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th

GlobeNewswire April 28, 2022

Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases

GlobeNewswire April 25, 2022

Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy

GlobeNewswire April 11, 2022

Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference

GlobeNewswire March 4, 2022

Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022

GlobeNewswire March 1, 2022

Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium

GlobeNewswire February 17, 2022

Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned

GlobeNewswire February 14, 2022

Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%

GlobeNewswire February 9, 2022

Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial

GlobeNewswire February 1, 2022

Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

GlobeNewswire January 31, 2022

Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th

GlobeNewswire January 26, 2022

Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer

GlobeNewswire January 10, 2022

Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022

GlobeNewswire January 3, 2022

Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia

GlobeNewswire December 13, 2021

Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

GlobeNewswire December 8, 2021

Veru Reports Record Fiscal 2021 Full-Year Financial Results

GlobeNewswire December 2, 2021

Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd

GlobeNewswire November 18, 2021

Veru Ranked as one of the Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500

GlobeNewswire November 18, 2021